Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).
James Chih-Hsin Yang
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Genentech; InnoPharma ; Lilly; Merck Serono; Novartis; Pfizer; Roche; Takeda
Honoraria - Abbott Laboratories; AstraZeneca; Bayer; Boehringer Ingelheim; Pfizer; Roche
Research Funding - Boehringer Ingelheim
Lecia V. Sequist
Consultant or Advisory Role - AstraZeneca (U); Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Boehringer Ingelheim
Martin H. Schuler
Research Funding - Boehringer Ingelheim
Tony Mok
Employment or Leadership Position - The Chinese University of Hong Kong
Consultant or Advisory Role - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Honoraria - Amgen; AstraZeneca; AVEO; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis; Eisai; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Pfizer; Roche; Taiho Pharmaceutical
Research Funding - AstraZeneca
Nobuyuki Yamamoto
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly
Kenneth John O'Byrne
Consultant or Advisory Role - Boehringer Ingelheim; Lilly
Honoraria - Boehringer Ingelheim; Lilly
Research Funding - Lilly
Vera Hirsh
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Sarayut Lucien Geater
No relevant relationships to disclose
Caicun Zhou
Consultant or Advisory Role - Boehringer Ingelheim; Clovis; Lilly; Roche
Dan Massey
Employment or Leadership Position - Boehringer Ingelheim
Victoria Zazulina
Employment or Leadership Position - Boehringer Ingelheim
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche; Sanofi